Posso ottenerlo?
Sì, se un medico ritiene che sia adatto a Lei. Liraglutide è autorizzato nell’UE e può essere prescritto dopo una valutazione medica.
LiraglutideSolo su prescrizione
Consulto medico online per Liraglutide.
Un medico autorizzato dall'UE esamina il Suo caso e, se idoneo, rilascia una prescrizione elettronica valida in qualsiasi farmacia dell'UE ai sensi della direttiva 2011/24/UE.
- Daily pen with flexible titration
- One of the longest-standing GLP-1s in Europe
- An option when a weekly GLP-1 isn't the right fit
Inizia consultoInizia consulto · 25 €/mese
Rimborso completo se una valutazione non viene approvata · Il farmaco, se prescritto, viene dispensato e pagato separatamente in farmacia.
IN PAROLE SEMPLICI
Cos’è Liraglutide e come ottenere un trattamento
Liraglutide è un medicinale somministrato con un’iniezione sotto la pelle una volta al giorno. Come semaglutide, imita l’ormone intestinale naturale GLP-1, che segnala al cervello che ha mangiato abbastanza, riducendo così la fame e il desiderio di cibo. Nell’UE viene venduta come Saxenda per il controllo del peso e si usa insieme a una dieta con meno calorie e più attività fisica. È autorizzata nell’UE per il controllo del peso da marzo 2015.
Liraglutide è autorizzato per l’uso nell’UE dal 23 marzo 2015. Un medico abilitato può quindi prescriverlo quando è clinicamente adatto a Lei.
Maggiori informazioni sui peptidi su Peptidepedia.
Cosa posso prendere al suo posto?
I nostri medici esaminano ogni opzione per Perdita di peso e consigliano quella più adatta alla Sua storia clinica e ai Suoi obiettivi.
Veda tutte le opzioni per Perdita di pesoCosa mostrano gli studi?
Tutti gli studi su Liraglutide sono elencati qui sotto con il numero di registro, il numero di partecipanti e l’indicazione se i risultati sono stati sottoposti a revisione paritaria o provengono da un annuncio dell’azienda.
Vada agli studiEVIDENZE VERIFICATE
Liraglutide: guida alle evidenze e alla regolamentazione.
CHE COS’È
Come agisce
It copies the gut hormone GLP-1, which increases the feeling of fullness and reduces hunger and food cravings.
- GLP-1
FASE DI SVILUPPO
Medicinale autorizzato nell’UE
Registro degli studi1 studi registrati
Ogni identificativo NCT rimanda al record ClinicalTrials.gov. Una comunicazione dei risultati non equivale a una pubblicazione sottoposta a revisione paritaria.
| STUDIO / NCT | POPOLAZIONE | PARTECIPANTI | STATO | RISULTATO / COMPLETAMENTO |
|---|---|---|---|---|
| SCALE Obesity and Prediabetes (NN8022-1839)NCT01272219 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with treated high blood pressure or abnormal blood fats, without type 2 diabetes; all received lifestyle counselling | 3,731 | Con risultati | 2015-07-02 |
Che cosa hanno riportato gli studi
I risultati sono separati per fonte e grado di evidenza, così i dati scientifici non vengono confusi con gli annunci del produttore.
Revisione paritaria
Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 (PMID 26132939)| DOSE O GRUPPO | VARIAZIONE MEDIA DEL PESO | SETTIMANE |
|---|---|---|
| 3.0 mg once daily | −8.0% | 56 |
| Placebo | −2.6% | 56 |
Everyone in the trial also received lifestyle counselling, people with type 2 diabetes were excluded, and the primary result covers 56 weeks only.
SEGNALI DI SICUREZZA IDENTIFICATI
Che cosa è stato segnalato con Liraglutide.
Nausea
Reported by 40.2% of people on liraglutide 3.0 mg versus 14.7% on placebo in the SCALE Obesity and Prediabetes trial.
Diarrhoea
Reported by 20.9% on liraglutide 3.0 mg versus 9.3% on placebo in the same trial.
Constipation
Reported by 20.0% on liraglutide 3.0 mg versus 8.7% on placebo in the same trial.
Vomiting
Reported by 16.3% on liraglutide 3.0 mg versus 4.1% on placebo in the same trial.
Gallstone problems
Acute gallstone events were reported by 2.3% on liraglutide 3.0 mg versus 0.9% on placebo across the EMA weight-management trial pool, mainly gallstones (1.5% versus 0.5%).
Acute pancreatitis
Independently confirmed in 7 people (0.2%) on liraglutide 3.0 mg versus 1 person (under 0.1%) on placebo across the EMA weight-management trial pool.
Serious side effects overall
Serious adverse events were reported in 6.2% of the liraglutide group versus 5.0% of the placebo group in the SCALE Obesity and Prediabetes trial.
25 €/mese (fatturati 25 € ogni 28 giorni)Avvia una consulenza medica
FormaPenna per iniezione pre-riempita
FrequenzaUna volta al giorno
RisultatiGradual, week by week
Quanto paghi a Hi-Doctor25 €/mese (fatturati 25 € ogni 28 giorni)
IN 60 SECONDI
Liraglutide in sintesi
- A GLP-1 receptor agonist given as an injection under the skin once a day.
- Adults with a BMI of 30 or more, or 27 or more plus a weight-related illness.
- One injection every day, at any time, built up from 0.6 mg to 3.0 mg.
- Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
Sul trattamento
Che cos'è Liraglutide?
Commercializzato anche come Saxenda, Victoza.
Principio attivo: Liraglutide · Dosaggi: 0.6 – 3 mg / day
Liraglutide is a GLP-1 receptor agonist given as a daily subcutaneous injection. It was one of the first in its class approved in Europe for weight management in adults with obesity, or overweight with comorbidities.
Compared with weekly GLP-1s, its daily dosing can be useful when flexibility of adjustment matters or when a semaglutide hasn't been tolerated. The doctor weighs this up in your consultation — two GLP-1 agonists are never combined.
COME AGISCE
Che cosa fa Liraglutide nel tuo corpo
Like other GLP-1 analogues, liraglutide mimics a natural gut hormone: it eases hunger signals and produces earlier fullness, so you tend to eat less. Being shorter-acting, its dose is adjusted day by day.
Copies one gut hormone
Liraglutide is a copy of a natural gut hormone called GLP-1, which the body releases after eating. The EU product information describes it as an acylated human GLP-1 analogue with 97% amino acid sequence homology to the human hormone, and it binds to and activates the GLP-1 receptor.
Raises fullness, lowers hunger
GLP-1 receptors also sit in brain regions that regulate appetite. The product information reports that liraglutide increases feelings of fullness and satiety while lowering hunger and prospective food consumption, so people eat less. It does not increase energy expenditure compared with placebo.
Short-acting, so taken daily
Liraglutide has an elimination half-life of roughly 13 hours, which is why it is injected once every day rather than once a week like semaglutide or tirzepatide. It also raises insulin and lowers glucagon in a glucose-dependent way, and weight is lost mainly as fat mass.
Come aiuta
Three ways it supports weight loss.
Eases appetite
Earlier fullness and calmer hunger signals through the day.
Flexible dosing
Daily titration lets the doctor fine-tune the dose to your tolerance.
Long EU history
Among the first weight-management GLP-1s approved in Europe.
Cosa aspettarsi
A gradual, week-by-week build-up.
Treatment starts at a low daily dose and steps up through the intermediate doses as tolerated. Your doctor sets the pace and adjusts if side effects appear.
- Week 1 · 0.6 mg daily starting dose
- Following weeks · Step up through 1.2, 1.8 and 2.4 mg as tolerated
- Maintenance · 3 mg daily when appropriate
- Ongoing · Follow-up through your account chat
Typical escalation
- Starting dose0.6 mg / day
- Step-ups1.2 → 1.8 → 2.4 mg / day
- Maintenance3 mg / day
Il Suo piano è personale
Questi passaggi sono solo indicativi. Il medico adatta il piano alla Sua risposta e tolleranza — e può scrivergli in qualsiasi momento.
NELLA VITA QUOTIDIANA
Usare Liraglutide nella vita quotidiana
Inject once every day
Liraglutide is injected once daily, at any time of day, with or without food. Unlike weekly injections it needs a dose every 24 hours, so it is easiest to pick a convenient time and keep to it.
Start low and build up
Treatment starts at 0.6 mg once daily and rises by 0.6 mg at intervals of at least a week, reaching the 3.0 mg maintenance dose in week 5. The slow climb is there to improve stomach and bowel tolerance.
Tummy, thigh or upper arm
The injection goes under the skin of the abdomen, the thigh or the upper arm. It must never be given into a vein or a muscle. Rotate the site each day to reduce the risk of amyloid deposits building up under the skin.
Check the pen before use
Look at the liquid before you inject. It should be clear and colourless, or almost colourless. With a new pen, do the flow check described in the instructions so you can see a drop appear at the needle tip before setting your dose.
Missed dose: the 12 hour rule
If you remember within 12 hours of your usual time, take the dose as soon as you can. If there is less than 12 hours until the next one, skip it and carry on as normal. Never take an extra dose.
Store pens in the fridge
Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, away from the freezer compartment, and must not be frozen. A pen in use can be stored below 30 degrees Celsius or refrigerated, and is discarded one month after first use.
Drink enough fluid
Nausea, vomiting and diarrhoea are common at the start and can leave you short of fluid. Dehydration has been linked to kidney impairment and acute kidney failure on GLP-1 medicines, so drink plenty and tell your doctor if you cannot keep fluids down.
Keep the diet and activity going
Liraglutide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the daily injection.
Sicurezza prima di tutto
La sicurezza, per intero.
Liraglutide è un farmaco efficace — e, come ogni farmaco, comporta dei rischi. Il medico verifica tutto questo prima di prescrivere. Ecco il quadro onesto, non solo una rassicurazione.
Effetti indesiderati, per frequenza
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe and lasting pain in the stomach area that may reach through to your back, which can signal pancreatitis
- Severe pain high in the tummy, usually worst on the right side under the ribs, which can signal gallstones or an inflamed gall bladder
- Breathing problems, or swelling of the face, lips, tongue or throat, which can signal a severe allergic reaction
- Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can lead to kidney failure
- Cold sweat, pale skin, shakiness, headache and confusion, if you also take insulin or a sulfonylurea for diabetes
- A racing or pounding heartbeat while you are resting, which the prescriber needs to review
- Severe stomach pain with bloating and no bowel movement, which can signal a blocked bowel
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea), most often while the dose is being increased
- Being sick (vomiting)
- Diarrhoea
- Constipation
- Headache
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Low blood sugar symptoms, self-reported and not confirmed by a blood glucose reading, in people without type 2 diabetes
- Trouble sleeping, mainly during the first three months
- Dizziness
- A change in the sense of taste
- Dry mouth
- Indigestion, gastritis or acid reflux
- Pain in the upper part of the tummy
- Wind, burping or a bloated tummy
- Gallstones
- Rash
- Injection site reactions
- Weakness or tiredness
- Raised lipase or amylase on blood tests
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Dehydration
- A faster heart rate (tachycardia)
- Pancreatitis, which is inflammation of the pancreas
- Delayed stomach emptying
- Inflammation of the gall bladder (cholecystitis)
- Nettle rash (urticaria)
- Generally feeling unwell
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Anaphylactic reaction, a sudden and severe whole-body allergic reaction
- Acute kidney failure
- Kidney impairment
Frequency not known
frequency not known (cannot be estimated from the available data)
reported, but nobody can yet say how often it happens
- Intestinal obstruction, a blockage of the bowel, reported after the medicine went on the market
- Cutaneous amyloidosis, a lumpy deposit that can build up under the skin at the injection site
Adulti con obesità (IMC ≥30) o sovrappeso (IMC ≥27) con almeno una condizione associata come diabete di tipo 2, ipertensione o dislipidemia.
- Autoiniezione giornaliera in coscia, addome o braccio, a qualsiasi ora ma idealmente sempre alla stessa.
- La dose si aumenta di settimana in settimana fino a quella di mantenimento, per limitare i disturbi digestivi.
- Funziona insieme a dieta e attività fisica — non sostituisce i cambiamenti dello stile di vita.
CHI NON DEVE ASSUMERLO E CHI RICHIEDE CAUTELA
- You have ever had an allergic reaction to liraglutide or to any other ingredient in the pen. This is the only absolute contraindication in the EU product information.
- You are pregnant, or you want to become pregnant. Liraglutide should not be used in pregnancy, and treatment is discontinued if pregnancy occurs.
- You are breastfeeding. It is not known whether liraglutide passes into human milk, so it should not be used while breastfeeding.
- You or a close relative have had medullary thyroid carcinoma, or you have multiple endocrine neoplasia syndrome type 2. US labelling makes this an outright contraindication; EU labelling advises caution in anyone with thyroid disease.
- You have had pancreatitis. If pancreatitis is suspected liraglutide is stopped, and if it is confirmed it is not restarted.
- You have gallstones or gall bladder disease. Weight-management trials found more gallstones and gall bladder inflammation on liraglutide than on placebo.
- You have severe kidney impairment, including end-stage kidney disease, or severe liver impairment. Liraglutide is not recommended in these groups.
- You have inflammatory bowel disease or diabetic gastroparesis. Experience is limited and the medicine is not recommended, because it causes stomach and bowel effects.
- You already take another GLP-1 receptor agonist, or you would be using it as a replacement for insulin. Neither is allowed.
- You have New York Heart Association class IV heart failure, or you are 75 years or older. There is no clinical experience in these groups, so use is not recommended.
Quando cercare assistenza urgente
In caso di sintomi gravi, improvvisi o inattesi, chiami il numero di emergenza locale o si rechi al pronto soccorso più vicino. Poi informi il medico tramite la chat del Suo account.
Farmaci e sostanze che interagiscono
| FARMACO O SOSTANZA | COSA PUÒ ACCADERE | COSA FA IL MEDICO |
|---|---|---|
| Insulin and sulfonylureas (for example gliclazide) | Combined use in type 2 diabetes raises the risk of low blood sugar, sometimes severe. | The prescriber may lower the insulin or sulfonylurea dose and asks for blood glucose self-monitoring. |
| Other GLP-1 receptor agonists | Two medicines acting on the same receptor add side effects without an established extra benefit. | Liraglutide for weight management must not be combined with another GLP-1 receptor agonist. |
| Warfarin and other coumarin blood thinners | No interaction study was done, and a clinically relevant effect on warfarin cannot be excluded. | The prescriber arranges more frequent INR checks when liraglutide is started. |
| Oral medicines in general | Liraglutide slightly delays stomach emptying, which can slow how fast a tablet is absorbed. | Interaction studies showed no clinically relevant delay, so no dose change is required. |
| Paracetamol | Peak paracetamol level fell by 31% and was reached up to 15 minutes later; total exposure was unchanged. | No dose adjustment is needed for paracetamol taken alongside liraglutide. |
| Combined oral contraceptives | Peak ethinylestradiol and levonorgestrel levels fell by 12% and 13%, with no relevant change in total exposure. | The contraceptive effect is expected to be unaffected, so no change is required. |
| Atorvastatin, digoxin and lisinopril | Peak levels fell by 38%, 31% and 27% respectively, with only small changes in total exposure. | No dose adjustment of any of these three is required based on those results. |
| General anaesthesia or deep sedation | Delayed stomach emptying can leave food in the stomach, and pulmonary aspiration has been reported. | Tell the anaesthetic team you take liraglutide before any procedure needing anaesthesia or sedation. |
Fai valutare il tuo caso da un medicoÈ esattamente ciò che il medico verifica prima di prescrivere qualsiasi cosa.
Leggi il riepilogo completo sulla sicurezza di LiraglutideEVIDENZE
Che cosa hanno rilevato gli studi clinici
The SCALE phase 3 programme tested liraglutide 3.0 mg once daily against placebo in 5,358 adults, and reported a mean body-weight change of -8.0% at 56 weeks compared with -2.6% on placebo.
3,731 adults with BMI >= 30, or >= 27 with dyslipidaemia or hypertension · 56 weeks
SCALE Obesity and Prediabetes. Placebo changed -2.6%. In kilograms the change was -8.4 kg versus -2.8 kg from a mean baseline of 106.3 kg.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics3,731 adults without type 2 diabetes · 56 weeks
In the same trial 26.6% of the placebo group reached 5%. For a loss of more than 10% the figures were 32.8% and 10.1%.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes at screening · 160 weeks
Placebo changed -1.8%. The weight loss occurred mainly in the first year and was sustained through week 160.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes and obesity or overweight · 160 weeks
Estimated time to onset of type 2 diabetes was 2.7 times longer on liraglutide, with a hazard ratio of 0.2 versus placebo.
Fonte: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics422 adults who had already lost at least 5% on a low-calorie diet · 56 weeks
SCALE Maintenance. Placebo changed -0.2%. 81.4% on liraglutide kept at least 5% of the run-in loss, versus 48.9% on placebo.
Fonte: SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight lossThese figures are group averages from randomised trials, not a prediction for any one person. Some participants lost far more than the average and some lost very little, and everyone in these trials was also following an energy-restricted diet with exercise counselling alongside the daily injection. The product information also notes that of the people who had lost less than 5% after 12 weeks on the full dose, 93.4% did not go on to reach a 10% loss at one year, which is why the prescriber reviews progress at that point.
ALTERNATIVE
Liraglutide vs other EU weight-management medicines
| FARMACO | COME SI ASSUME | OGNI QUANTO | INTERVALLO DI DOSE ABITUALE | INDICAZIONE AUTORIZZATA NELL'UE | EVIDENZA PRINCIPALE |
|---|---|---|---|---|---|
| Semaglutide | Iniezione settimanale | Una volta a settimana | 0.25–2.4 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | STEP 1: mean -14.9% body weight at 68 weeks versus -2.4% placebo |
| Tirzepatide | Iniezione settimanale | Una volta a settimana | 2.5–15 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | SURMOUNT-1: mean -20.9% body weight at 72 weeks versus -3.1% placebo |
| Orlistat | Capsula orale | Con ogni pasto principale | 120 mg per main meal | In conjunction with a mildly hypocaloric diet, for obese patients with BMI ≥30, or overweight patients with BMI ≥28 and associated risk factors. | XENDOS: mean 5.8 kg lost at four years versus 3.0 kg on placebo |
Non sai quale sia adatto al tuo caso? Il medico esamina la tua storia clinica e te lo dice.
Inizia consulto · 25 €/meseACCESSO E COSTI
Come ottenere Liraglutide e quanto costa
Liraglutide is a centrally authorised medicine that is subject to medical prescription across the European Union, so no pharmacy can supply it without a valid prescription from a doctor. Who pays varies a lot by country: most national health systems do not cover it for weight management, so the patient pays the pharmacy directly. The entries for Spain, Germany, the Netherlands, Portugal, Ireland and Poland come from the national sources listed below; the rows for France, Italy, Belgium and Austria record the general position for this indication and are not confirmed against a national decision. The national database linked on each row is the authority on the current position.
Quanto paghi a Hi-Doctor
25 €/mese (fatturati 25 € ogni 28 giorni)
Risponda ad alcune domande e un medico autorizzato dall'UE esaminerà il Suo caso in meno di 2 ore in media. Rimborso completo se non fa per Lei.
Quanto addebita la farmacia
Hi-Doctor non vende, non detiene e non dispensa farmaci e non ne stabilisce il prezzo. Il farmaco si paga separatamente in farmacia e l'importo dipende dal paese, dalla confezione, dalla disponibilità di un generico e dalla rimborsabilità. La banca dati ufficiale collegata nella tabella pubblica il prezzo autorizzato in vigore.
| PAESE | REGIME DI FORNITURA | RIMBORSATO DAL SISTEMA SANITARIO? | FONTE UFFICIALE |
|---|---|---|---|
| Spagna | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | AEMPS CIMA |
Mostra gli altri paesi
| Germania | Medicinale soggetto a prescrizione medica | Excluded from statutory health insurance as a weight-regulation medicine | PharmNet.Bund AMIce |
|---|---|---|---|
| Francia | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | Base de données publique des médicaments |
| Italia | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | AIFA Medicinali |
| Paesi Bassi | Medicinale soggetto a prescrizione medica | Restricted, conditions set in Regeling zorgverzekering bijlage 2 | CBG-MEB Geneesmiddeleninformatiebank |
| Portogallo | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | INFARMED Infomed |
| Belgio | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Irlanda | Medicinale soggetto a prescrizione medica | Reimbursed by the HSE since January 2023, see national criteria | HPRA Find a Medicine |
| Austria | Medicinale soggetto a prescrizione medica | Not reimbursed for weight management | BASG Medikamente Info Austria |
| Polonia | Medicinale soggetto a prescrizione medica | Not reimbursed, patient pays in full | Rejestr Produktów Leczniczych |
PREZZI
Paghi solo se il trattamento è approvato.
25 €/mese per il controllo del peso o 15 €/mese (fatturati 45 € ogni 90 giorni) per la crescita dei capelli. Per la salute sessuale è disponibile una consultazione una tantum da 35 €.
Perdita di peso
PIANO CONTINUATIVO
25 €/mese
Fatturati 25 € ogni 28 giorni · annulli quando vuoi
Ciclo di trattamento di 28 giorni
Per un trattamento continuativo e rinnovi valutati dal Suo medico.
Rinnovi valutati dal Suo medico
Inizia consulto
Rimborso completo se una valutazione non viene approvata
COSA È INCLUSO
- Primo consulto incluso
- Rinnovi valutati dal Suo medico
- Assistenza continuativa con il Suo medico
- Può disdire in qualsiasi momento
Rimborso completo se una valutazione non viene approvata
Se una valutazione non viene approvata, rimborsiamo la quota di 25 € di quel periodo e annulliamo il piano.
Nota: Il farmaco, se prescritto dal medico, viene pagato separatamente in farmacia al prezzo stabilito. Hi-Doctor non vende farmaci.
COME DECIDE IL MEDICO
Il tuo caso lo valuta un medico abilitato, non un algoritmo
Un medico abilitato nell'UE legge il tuo questionario e risponde in meno di 2 ore in media.
Se il medico decide che non è sicuro prescrivere, il costo della consulenza viene rimborsato per intero.
Il follow-up avviene nella chat privata del tuo account, nel rispetto del GDPR. Niente WhatsApp, niente SMS.
DOMANDE FREQUENTI
Domande su Liraglutide.
ALTRI TRATTAMENTI PERDITA DI PESO
Esplora i trattamenti correlati.
FONTI
Da dove provengono queste informazioni
- 01
Saxenda (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2015
- 02
Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics — European Medicines Agency, 2026
- 03
Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 04
Saxenda 6 mg/mL solution for injection in pre-filled pen: Patient Information Leaflet — electronic medicines compendium (emc), 2026
- 05
Liraglutide (Saxenda, Diavic, Zegluxen): NHS medicines A to Z — NHS, 2026
- 06
SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management — New England Journal of Medicine, 2015
- 07
SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss — International Journal of Obesity, 2013
- 08
Victoza (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2009
- 09
Saxenda (liraglutide) injection: US prescribing information, boxed warning and contraindications — DailyMed, US National Library of Medicine, 2026
- 10
CIMA: Saxenda presentations, marketing and prescription status in Spain — AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
- 11
Sozialgesetzbuch V § 34: medicines excluded from statutory health insurance, including those for weight regulation — Bundesministerium der Justiz (gesetze-im-internet.de), 2026
- 12
Liraglutide: preparaattekst and vergoeding conditions in the Netherlands — Farmacotherapeutisch Kompas, Zorginstituut Nederland, 2026
- 13
Liraglutide (Saxenda): health technology assessment and HSE reimbursement decision — National Centre for Pharmacoeconomics (Ireland), 2023
- 14
Rejestr Produktow Leczniczych: Saxenda registration record in Poland — Centrum e-Zdrowia (Poland), 2026
- 15
INFOMED: base de dados de medicamentos de uso humano — INFARMED (Portugal), 2026
- 16
STEP 1: Once-weekly semaglutide in adults with overweight or obesity — New England Journal of Medicine, 2021
- 17
SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine, 2022
- 18
XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study — Diabetes Care, 2004
- 19
Wegovy (semaglutide) solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 20
Xenical 120 mg hard capsules: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
Revisionato dal team medico di Hi-Doctor · Ultima revisione 2026-07-27 · Prossima revisione prevista il 2027-07-27
Questa pagina contiene informazioni su un farmaco: non è una raccomandazione ad assumerlo né sostituisce una visita medica. Solo un medico abilitato che abbia esaminato la tua storia clinica può stabilire se un trattamento è adatto a te.
Scopra se fa per Lei
Verifichi se Liraglutide è appropriato per Lei.
Risponda ad alcune domande e un medico autorizzato dall'UE esaminerà il Suo caso in meno di 2 ore in media. Rimborso completo se non fa per Lei.